Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far

Creative Commons License

Castillo J. J., Beltran B. E., Miranda R. N., PAYDAŞ S., Winer E. S., Butera J. N.

ONCOLOGIST, cilt.16, sa.1, ss.87-96, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 1
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1634/theoncologist.2010-0213
  • Dergi Adı: ONCOLOGIST
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.87-96
  • Anahtar Kelimeler: EBV, Epstein-Barr virus, Diffuse large B-cell lymphoma, DLBCL, Elderly, Review, NERVOUS-SYSTEM LYMPHOMA, LYMPHOPROLIFERATIVE DISORDERS, HODGKIN LYMPHOMA, JAPANESE POPULATION, DISEASE, EXPRESSION, CHOP, ASSOCIATION, LMP1, TRANSFORMATION
  • Çukurova Üniversitesi Adresli: Evet

Özet

Epstein-Barr virus-positive (EBV-positive) diffuse large B-cell lymphoma (DLBCL) of the elderly is a newly described lymphoproliferative disorder recently included as a "provisional" entity in the most current WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. The objective of this review is to provide a thorough and current summary of the existing knowledge of this subtype of DLBCL. We will review and discuss the incidence of EBV expression in DLBCL, the pathogenesis behind EBV-driven malignant transformation of B cells, the different EBV latency patterns associated with DLBCL, the distinct pathologic characteristics of EBV-positive DLBCL, the potential predictive and prognostic value of EBV tumoral status in patients with DLBCL, and potential strategies for the treatment of this rare entity, which is characterized by a suboptimal response to therapy and poor survival rate. The Oncologist 2011; 16: 87-96